Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 11641425
Kim H, et al. (2001) Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging. Mol Pharmacol 60, 972-80 11641425
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y1034-p - JAK1 (human)
Modsite: AIEtDkEyytVkDDR SwissProt Entrez-Gene
Orthologous residues
JAK1 (human): Y1034‑p, JAK1 (mouse): Y1033‑p, JAK1 (rat): Y1078‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  FRTL-5 (thyroid cell)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase
methimazole IFN-gamma inhibit treatment-induced increase
H2O2 increase

Y1035-p - JAK1 (human)
Modsite: IEtDkEyytVkDDRD SwissProt Entrez-Gene
Orthologous residues
JAK1 (human): Y1035‑p, JAK1 (mouse): Y1034‑p, JAK1 (rat): Y1079‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  FRTL-5 (thyroid cell)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase
methimazole IFN-gamma inhibit treatment-induced increase
H2O2 increase

Y1007-p - JAK2 (human)
Modsite: VLPQDKEyyKVkEPG SwissProt Entrez-Gene
Orthologous residues
JAK2 (human): Y1007‑p, JAK2 (mouse): Y1007‑p, JAK2 (rat): Y1007‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  FRTL-5 (thyroid cell)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase
methimazole IFN-gamma inhibit treatment-induced increase
H2O2 increase

Y1008-p - JAK2 (human)
Modsite: LPQDKEyyKVkEPGE SwissProt Entrez-Gene
Orthologous residues
JAK2 (human): Y1008‑p, JAK2 (mouse): Y1008‑p, JAK2 (rat): Y1008‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  FRTL-5 (thyroid cell)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase
methimazole IFN-gamma inhibit treatment-induced increase
H2O2 increase

Y701-p - STAT1 (rat)
Modsite: DDPKRTGyIKTELIS SwissProt Entrez-Gene
Orthologous residues
STAT1 (human): Y701‑p, STAT1 iso2 (human): Y701‑p, STAT1 (mouse): Y701‑p, STAT1 (rat): Y701‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  FRTL-5 (thyroid cell)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase
methimazole IFN-gamma inhibit treatment-induced increase
H2O2 increase
methimazole H2O2 inhibit treatment-induced increase

Y705-p - STAT3 (rat)
Modsite: DPGSAAPyLKTKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  FRTL-5 (thyroid cell)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IFN-gamma increase
methimazole IFN-gamma inhibit treatment-induced increase
H2O2 increase
methimazole H2O2 inhibit treatment-induced increase